Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 10093977)

1.

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R.

Lancet. 1999 Mar 13;353(9156):863-8.

PMID:
10093977
3.

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.

Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, Bucher HC, Bernasconi E, Weber R; Swiss Cohort Study.

AIDS. 2001 Sep 28;15(14):1793-800.

PMID:
11579241
4.

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B.

Arch Intern Med. 2000 Apr 24;160(8):1123-32.

PMID:
10789605
5.

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.

Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration.

Lancet. 2003 Aug 30;362(9385):679-86.

PMID:
12957089
6.
7.

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.

Antivir Ther. 2008;13(7):927-36.

PMID:
19043927
8.

Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.

Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.

AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1631-8.

PMID:
10606086
9.

Virological rebound after suppression on highly active antiretroviral therapy.

Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD; EuroSIDA study group.

AIDS. 2003 Aug 15;17(12):1741-51.

PMID:
12891060
10.
11.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
12.

How reliable is an undetectable viral load?

Combescure C, Vallier N, Ledergerber B, Cavassini M, Furrer H, Rauch A, Battegay M, Bernasconi E, Vernazza P, Hirschel B; Swiss HIV Cohort Study.

HIV Med. 2009 Sep;10(8):470-6. doi: 10.1111/j.1468-1293.2009.00714.x. Epub 2009 May 6.

PMID:
19459990
13.

Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy.

van den Berg JB, Hak E, Vervoort SC, Hoepelman IM, Boucher CA, Schuurman R, Schneider MM.

HIV Med. 2005 Sep;6(5):299-306.

PMID:
16156876
14.

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration.

HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8.

PMID:
21059167
15.

Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.

Jevtović D, Dragovic G, Salemović D, Ranin J, Kušić J, Marinković J, Djurković-Djaković O.

Biomed Pharmacother. 2014 Apr;68(3):391-5. doi: 10.1016/j.biopha.2014.01.001. Epub 2014 Jan 15.

PMID:
24486106
16.

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance.

Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502.

17.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

Pursuing Later Treatment Option II (PLATO II) project team; Observational HIV Epidemiological Research Europe (COHERE) Group, Castagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, Garcia F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Fabre-Colin C, Kjaer J, Grarup J, Costagliola D, Lodwick R, Ledergerber B, Phillips A.

Lancet Infect Dis. 2012 Feb;12(2):119-27. doi: 10.1016/S1473-3099(11)70248-1. Epub 2011 Oct 9.

18.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

19.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
20.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration.

Lancet. 2002 Jul 13;360(9327):119-29. Erratum in: Lancet 2002 Oct 12;360(9340):1178.

PMID:
12126821
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk